HC Wainwright & Co. Reiterates Buy on ProPhase Labs, Maintains $15 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates ProPhase Labs (NASDAQ:PRPH) with a Buy and maintains $15 price target.
HC Wainwright & Co. Reiterates Buy on Alto Ingredients, Maintains $10 Price Target
HC Wainwright & Co. analyst Amit Dayal reiterates Alto Ingredients (NASDAQ:ALTO) with a Buy and maintains $10 price target.
Needham Reiterates Buy on Avadel Pharmaceuticals, Maintains $11 Price Target
Needham analyst Ami Fadia reiterates Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy and maintains $11 price target.
AppLovin Is Vulnerable To Hyper-Casual Headwinds, Further Hampered By Google’s Ad Restrictions, Analyst Says
Benchmark analyst Mark Zgutowicz reiterated Sell on AppLovin Corp (NASDAQ:APP) with a $7.00 price target. The consensus does not reflect ’23 hyper-casual…
Disney Analyst Expects Blockbusters Wakanda Forever, Avtar To Dominate Upcoming Quarterly Results
Keybanc analyst Brandon Nispel reiterated Overweight on The Walt Disney Co (NYSE:DIS) with a $119.00 price target. The analyst expected a significant…
Sage Therapeutics-Biogen Partnered Depression Candidate Under Priority FDA Review, Analyst Says Its ‘Incrementally Positive’
The FDA has accepted for review a marketing application seeking approval for Sage Therapeutics Inc (NASDAQ:SAGE) and Biogen Inc’s (NASDAQ:BIIB) zuranolone for major depressive…
Why These Uber Analysts Are Bullish Ahead Of Q4 Earnings
Uber Technologies Inc. (NYSE: UBER) will issue its fourth-quarter 2022 earnings on Feb. 8 before market open, here’s what the Street is expecting.
JMP Securities Reiterates Market Outperform on Kemper, Maintains $85 Price Target
JMP Securities analyst Matthew Carletti reiterates Kemper (NYSE:KMPR) with a Market Outperform and maintains $85 price target.
JMP Securities Reiterates Market Outperform on CTI BioPharma, Maintains $9 Price Target
JMP Securities analyst Reni Benjamin reiterates CTI BioPharma (NASDAQ:CTIC) with a Market Outperform and maintains $9 price target.
HC Wainwright & Co. Reiterates Buy on Gracell Biotechnologies, Maintains $12 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates Gracell Biotechnologies (NASDAQ:GRCL) with a Buy and maintains $12 price target.